Valuation : Imugene Limited

Market Cap 30.85M 22.25M 19.14M 18.03M 16.42M 30.73M 2.12B 214M 82.57M 1.08B 83.54M 81.72M 3.42B P/E 2027 *
-0.8x
P/E 2028 * -1.06x
Enterprise Value 29.85M 21.53M 18.52M 17.44M 15.89M 29.73M 2.05B 207M 79.89M 1.04B 80.83M 79.07M 3.31B EV / Sales 2027 *
-
EV / Sales 2028 * -
Free-Float
96.9%
Yield 2027 *
-
Yield 2028 * -
1 day-3.08%
1 week-7.35%
Current month-7.35%
1 month-25.88%
3 months-31.52%
6 months-73.19%
Current year-82.74%
1 week 0.06
Extreme 0.062
0.07
1 month 0.06
Extreme 0.062
0.08
Current year 0.06
Extreme 0.062
0.41
1 year 0.06
Extreme 0.062
0.46
3 years 0.06
Extreme 0.062
5.1
5 years 0.06
Extreme 0.062
21.25
10 years 0.06
Extreme 0.062
21.25
Manager TitleAgeSince
Director of Finance/CFO - 04/03/2025
Chief Tech/Sci/R&D Officer - 01/09/2023
Chief Tech/Sci/R&D Officer - 01/01/2022
Director TitleAgeSince
Chairman 70 31/10/2012
Director/Board Member 66 23/04/2019
Director/Board Member 61 07/09/2022
Date Insider Type Main position Quantity % Market Cap. Importance
19/12/25 Free

Director

14,706 0.0047%
19/12/25 Free

Director

29,411 0.0093%
19/12/25 Exercice

Director

14,706 0.0047%
Change 5-day change 1-year change 3-year change Capi.($)
-3.08%-7.35%-77.50%-96.96% 22.99M
-3.24%-6.89%-5.65%+11.20% 48.01B
+0.17%-1.04%+405.80%+546.58% 44.44B
-0.86%-0.53%+36.92%+20.35% 42.67B
-0.14%-2.13%+1.31%+82.21% 39.96B
0.00%-2.61%+13.09%+42.33% 32.75B
-3.44%+0.22% - - 17.74B
-0.78%+0.53%+19.14%+116.26% 16.49B
-0.37%-0.87%+10.98%+30.93% 14.38B
-0.86%-1.41%+71.82%+39.36% 13.4B
Average -1.26%-0.92%+52.88%+88.03% 26.99B
Weighted average by Cap. -1.04%-1.10%+84.29%+131.89%

Financials

2027 *2028 *
Net sales - -
Net income -42.79M -30.85M -26.55M -25M -22.78M -42.62M -2.94B -296M -115M -1.5B -116M -113M -4.74B -33.44M -24.11M -20.75M -19.54M -17.8M -33.31M -2.29B -232M -89.5M -1.17B -90.55M -88.58M -3.7B
Net Debt -1M -721K -620K -584K -532K -996K -68.62M -6.92M -2.68M -34.96M -2.71M -2.65M -111M -5.2M -3.75M -3.23M -3.04M -2.77M -5.18M -357M -36.01M -13.92M -182M -14.08M -13.77M -576M
Logo Imugene Limited
Imugene Limited is a clinical-stage immune-oncology company. It is engaged in developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Its platform technology seeks to harness and promote the body’s immune system against cancerous tumors. Its product pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug Azer-Cel (azercabtagene zapreleucel) which targets CD19 to attack blood cancer. Its pipeline includes an Oncolytic Virus and B-Cell Immunotherapies aimed at treating a variety of cancers in combination with standard of care drugs and immunotherapies. Its lead candidate is a chimeric vaccinia (pox) virus known as CF33, which is a combination of genomic sequences from multiple vaccinia virus strains to generate a new, safer and more potent virus. Its Chimeric antigen receptor (CAR)-engineered T cells (CAR T) are T cells redirected against tumors through engineered expression of CARs.
Employees
14
Date Price Change Volume
09/09/26 A$0.0630 -3.08% 5,130,624
08/09/26 A$0.0650 -4.41% 1,163,363
07/09/26 A$0.0680 -1.45% 1,535,518
04/09/26 A$0.0690 +4.55% 1,360,438
03/09/26 A$0.0660 -2.94% 1,064,652
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.0630AUD
Average target price
0.3067AUD
Spread / Average Target
+386.78%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!